# A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

> **NCT02991911** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** MEDI3726 Post-Chemo
- **BIOLOGICAL:** MEDI3726 Pre-Chemo
- **BIOLOGICAL:** MEDI3726 & Enzalutamide Combo

## Key facts

- **NCT ID:** NCT02991911
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-06
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991911, "A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02991911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*